Insider Selling: Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells 37,799 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider owned 9,174,453 shares in the company, valued at $155,965,701. The trade was a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Eli Samaha also recently made the following trade(s):

• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total value of $428,712.51.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Performance

Shares of TBPH traded down $0.02 on Wednesday, hitting $16.98. 1,319,960 shares of the stock traded hands, compared to its average volume of 689,283. Theravance Biopharma, Inc. has a one year low of $10.82 and a one year high of $21.03. The company has a market capitalization of $875.32 million, a PE ratio of 7.72 and a beta of 0.17. The business has a 50 day simple moving average of $16.56 and a 200 day simple moving average of $17.29.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The business had revenue of $17.70 million during the quarter. On average, equities analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently made changes to their positions in TBPH. Vanguard Group Inc. grew its position in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares in the last quarter. State Street Corp increased its position in Theravance Biopharma by 4.4% during the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after purchasing an additional 45,987 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 124,658 shares during the period. Geode Capital Management LLC grew its position in shares of Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after buying an additional 40,734 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at $10,611,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on TBPH. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. B. Riley Financial increased their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. TD Cowen upped their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. Finally, Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. One analyst has rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.